Company intelligence / Profile preview

RxAll

New Haven, Connecticut, United Statesrxall.net ↗

Ownership: Private
Development stage: Other

Overview

RxAll has developed a suite of digital health tools including the patented handheld "RxScanner" device that uses molecular sensing and AI to authenticate medicines in real time with high accuracy. Its platforms are used by thousands of pharmacies across Africa to ensure access to verified medications. The company’s technology has been adopted by regulatory agencies and healthcare providers in multiple countries to combat counterfeit drugs. Over 2.5 million patients per month benefit from its network. No clinical trials as it does not develop therapeutics.

Modalities: DeviceSoftwareArtificial IntelligenceIoT
Industry: Digital Health Medical Devices

Partnerships

Regulatory agencies in Africa (e.g., country FDAs)hospital networkspharmacy chains

Beyond the preview

Go deeper on RxAll.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RxAll.

Explore the full profile